- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Lobe Sciences Ltd (2): Lobe Sciences ends FY 2025 with cash of $5.85-million | 1 | Stockwatch | ||
| Do | Lobe Sciences Ltd.: Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy | 126 | ACCESS Newswire | Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical... ► Artikel lesen | |
| Di | Lobe Sciences Ltd (2): Lobe Sciences has cash of $5.85-million at Aug. 31 | 1 | Stockwatch | ||
| Di | Lobe Sciences Ltd.: Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition | 228 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in... ► Artikel lesen | |
| 24.10.25 | Lobe Sciences Ltd.: Lobe Sciences Completes Debt Settlement to Improve Balance Sheet | 311 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / October 23, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies... ► Artikel lesen | |
| 09.10.25 | Lobe Sciences Ltd (2): Lobe Sciences arranges $137,130 (U.S.) debt settlement | 4 | Stockwatch | ||
| 09.10.25 | Lobe Sciences Ltd.: Lobe Sciences Improves Balance Sheet | 219 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops... ► Artikel lesen | |
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 16.09.25 | ArcStone US Corp.: Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto | 620 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 15, 2025) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical... ► Artikel lesen | |
| 10.09.25 | Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025 | 457 | ACCESS Newswire | VANCOUVER, B.C. / ACCESS Newswire / September 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 09.09.25 | Lobe Sciences Ltd.: Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors | 401 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on... ► Artikel lesen | |
| 15.08.25 | Lobe Sciences Ltd.: Lobe Sciences Announces the Closing of the Previously Announced Private Placement | 463 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company")... ► Artikel lesen | |
| 29.07.25 | Lobe Sciences Ltd (2): Lobe Sciences arranges private placement | 2 | Stockwatch | ||
| 29.07.25 | Lobe Sciences Ltd (2): Lobe Sciences hires ArcStone for advisory services | 1 | Stockwatch | ||
| 29.07.25 | Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory | 482 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases... ► Artikel lesen | |
| 29.07.25 | Lobe Sciences Ltd.: Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes | 493 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. ("Lobe Sciences"... ► Artikel lesen | |
| 17.07.25 | Lobe Sciences Ltd (2): Lobe Sciences issues 546,206 shares for debt of $11,596 | 2 | Stockwatch | ||
| 17.07.25 | Lobe Sciences announces debt settlement | - | Seeking Alpha | ||
| 17.07.25 | Lobe Sciences Ltd. Announces Debt Settlement | 437 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases... ► Artikel lesen | |
| 08.07.25 | Lobe Sciences Ltd.: Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease | 735 | ACCESS Newswire | European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease.Covers... ► Artikel lesen | |
| 18.06.25 | Lobe Sciences Ltd.: Lobe Sciences Moves Forward with Development of Conjugated Psilocin Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals | 359 | ACCESS Newswire | New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin$6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,385 | +1,05 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| ATAIBECKLEY | 3,745 | -5,67 % | XFRA B72: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILATAIBECKLEY INC.... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,008 | +1,20 % | SOL Global Investments Corp.: SOL Global Announces Share Consolidation | Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL" or the "Company") announces that a majority vote by its Board of Directors... ► Artikel lesen | |
| ENTHEON BIOMEDICAL CORP | 0,045 | +1,12 % | Entheon Biomedical Corp.: Entheon Announces Letter of Intent with Nutravisor Inc. | Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has... ► Artikel lesen | |
| CYBIN | 6,450 | +1,57 % | Cybin Inc (2): Cybin starts trading on Nasdaq | ||
| REVIVE THERAPEUTICS | 0,001 | -95,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | Rapid Dose Therapeutics Corp.: Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt | Burlington, Ontario--(Newsfile Corp. - January 5, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that pursuant to the terms of its amended and restated... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,610 | +29,69 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 54,30 | +29,49 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| AKTIS ONCOLOGY | 22,460 | 0,00 % | Aktis Oncology: Erster US-Börsengang des Jahres - die Hintergründe | Die Wall Street kann sich in Kürze über ein weiteres Biotech-Unternehmen freuen. Der Radiopharma-Spezialist Aktis Oncology strebt an die Nasdaq und will mit dem Listing einen dreistelligen Millionen-Dollar-Betrag... ► Artikel lesen | |
| QIAGEN | 41,230 | -0,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 26,245 | +12,74 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,805 | -0,18 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 24,250 | -4,19 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines... ► Artikel lesen |
Das Unternehmen LOBE SCIENCES LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +38,30 % bei einem Aktienkurs von 0,033 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.